share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Dar Zavain

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Dar Zavain

Recursion Pharmaceuticals | 4：持股变动声明-董事 Dar Zavain
美股sec公告 ·  06/05 18:17
Moomoo AI 已提取核心信息
Recursion Pharmaceuticals, Inc. (RXRX) reported that Dar Zavain, a person associated with the company, was granted 13,097 shares of Class A Common Stock on June 3, 2024. The transaction was completed at no cost to the recipient, indicating that the shares were likely awarded as part of a compensation package or incentive plan. Following this transaction, Zavain's direct holdings in the company increased to a total of 102,153 shares. The grant is part of the company's ongoing efforts to align the interests of its key personnel with those of its shareholders.
Recursion Pharmaceuticals, Inc. (RXRX) reported that Dar Zavain, a person associated with the company, was granted 13,097 shares of Class A Common Stock on June 3, 2024. The transaction was completed at no cost to the recipient, indicating that the shares were likely awarded as part of a compensation package or incentive plan. Following this transaction, Zavain's direct holdings in the company increased to a total of 102,153 shares. The grant is part of the company's ongoing efforts to align the interests of its key personnel with those of its shareholders.
Recursion Pharmaceuticals，Inc. （RXRX）报告称，公司有关人士Dar Zavain于2024年6月3日获得了13,097股A类普通股。该交易对收件人没有费用，表明这些股票很可能是作为补偿计划或激励计划的一部分授予的。此次交易后，Zavain在公司的直接持股增加到了总共102,153股。此次授予是公司与其关键人员利益对齐持续努力的一部分。
Recursion Pharmaceuticals，Inc. （RXRX）报告称，公司有关人士Dar Zavain于2024年6月3日获得了13,097股A类普通股。该交易对收件人没有费用，表明这些股票很可能是作为补偿计划或激励计划的一部分授予的。此次交易后，Zavain在公司的直接持股增加到了总共102,153股。此次授予是公司与其关键人员利益对齐持续努力的一部分。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息